Search research articles
Contact Us
Filters
Showing results (661-670 of 703) with videos related to
Page
of 71
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 12, 2016
Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial
Marjan Ghiti Moghadam, Harald E Vonkeman, Peter M Ten Klooster, et al.
Rheumatology (Oxford, England)
|
April 21, 2016
Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout
Humaira Rasheed, Amanda J Phipps-Green, Ruth Topless, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
April 17, 2021
Prognostic role of proliferating CD8<sup>+</sup> cytotoxic Tcells in human cancers
Niclas C Blessin, Wenchao Li, Tim Mandelkow, et al.
BMC Rheumatology
|
June 22, 2019
Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment
Marjan Ghiti Moghadam, Femke B G Lamers-Karnebeek, Harald E Vonkeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
Karlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y J L Jansen, E A Rozeman, R Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2021
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
Hanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, et al.
Plos One
|
May 24, 2018
Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment
Marjan Ghiti Moghadam, Femke B G Lamers-Karnebeek, Harald E Vonkeman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 11, 2018
An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial
An Tran-Duy, Marjan Ghiti Moghadam, Martijn A H Oude Voshaar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
J M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Page
of 71
Search research articles
Search
Showing results (661-670 of 703) with videos related to
Sort By:
Page
of 71
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 12, 2016
Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial
Marjan Ghiti Moghadam, Harald E Vonkeman, Peter M Ten Klooster, et al.
Rheumatology (Oxford, England)
|
April 21, 2016
Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout
Humaira Rasheed, Amanda J Phipps-Green, Ruth Topless, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
April 17, 2021
Prognostic role of proliferating CD8<sup>+</sup> cytotoxic Tcells in human cancers
Niclas C Blessin, Wenchao Li, Tim Mandelkow, et al.
BMC Rheumatology
|
June 22, 2019
Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment
Marjan Ghiti Moghadam, Femke B G Lamers-Karnebeek, Harald E Vonkeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
Karlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y J L Jansen, E A Rozeman, R Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2021
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
Hanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, et al.
Plos One
|
May 24, 2018
Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment
Marjan Ghiti Moghadam, Femke B G Lamers-Karnebeek, Harald E Vonkeman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 11, 2018
An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial
An Tran-Duy, Marjan Ghiti Moghadam, Martijn A H Oude Voshaar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
J M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Page
of 71